Abstract
The tumor necrosis factor (TNF) gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving epigenetic mechanisms or miRNAs. A better knowledge of the molecular mechanisms that control TNF gene regulation and TNF signalling will provide deeper understanding of the initiation and development of apoptotic and inflammatory processes triggered by TNF cytokine in the gut. The described efforts to embed TNF in clinical treatment regiments reflect its attractive effectiveness in killing tumor cells. Whether the described strategies will achieve the success of incorporating TNF in lower gastrointestinal tract therapy for inflammatory diseases and cancer remains to be determined.
Keywords: TNF signalling, apoptosis, colorectal tumor cells, radiotherapy, intestinal epithelial cells, immune cells, tumor necrosis factor (TNF), cancer, Apoptosis, cytotoxic therapy
Current Pharmaceutical Biotechnology
Title:Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Volume: 13 Issue: 11
Author(s): Natalya Benderska, Saritha Chakilam, Manuela Hugle, Jelena Ivanovska, Muktheshwar Gandesiri, Jan Schulze-Luhrmann, Khuloud Bajbouj, Ronald Croner and Regine Schneider-Stock
Affiliation:
Keywords: TNF signalling, apoptosis, colorectal tumor cells, radiotherapy, intestinal epithelial cells, immune cells, tumor necrosis factor (TNF), cancer, Apoptosis, cytotoxic therapy
Abstract: The tumor necrosis factor (TNF) gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving epigenetic mechanisms or miRNAs. A better knowledge of the molecular mechanisms that control TNF gene regulation and TNF signalling will provide deeper understanding of the initiation and development of apoptotic and inflammatory processes triggered by TNF cytokine in the gut. The described efforts to embed TNF in clinical treatment regiments reflect its attractive effectiveness in killing tumor cells. Whether the described strategies will achieve the success of incorporating TNF in lower gastrointestinal tract therapy for inflammatory diseases and cancer remains to be determined.
Export Options
About this article
Cite this article as:
Benderska Natalya, Chakilam Saritha, Hugle Manuela, Ivanovska Jelena, Gandesiri Muktheshwar, Schulze-Luhrmann Jan, Bajbouj Khuloud, Croner Ronald and Schneider-Stock Regine, Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review, Current Pharmaceutical Biotechnology 2012; 13 (11) . https://dx.doi.org/10.2174/138920112802501971
DOI https://dx.doi.org/10.2174/138920112802501971 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Developments of DNA-dependent Protein Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics Paralog Specific Hsp90 Inhibitors – A Brief History and a Bright Future
Current Topics in Medicinal Chemistry Is HIV Involved in the Pathogenesis of Non-Infectious Pulmonary Complications in Infected Patients?
Current HIV Research Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging The Role of Immune and Inflammatory Mechanisms in ALS
Current Molecular Medicine Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy
Current Gene Therapy Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles
Current Gene Therapy Meet Our Editorial Board Member
Current Drug Therapy A179L, a New Viral Bcl2 Homolog Targeting Beclin 1 Autophagy Related Protein
Current Molecular Medicine New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews The Chemical Methods of Disulfide Bond Formation and Their Applications to Drug Conjugates
Current Organic Chemistry Shared Signaling Pathways Between Endocrine and Immune System Receptors: The Model of Gamma Chain
Current Signal Transduction Therapy Spontaneous Pneumothorax
Current Respiratory Medicine Reviews Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Natural Products as Anti-Invasive and Anti-Metastatic Agents
Current Medicinal Chemistry Using a Hybrid Radioenhancer to Discover Tumor Cell-targeted Treatment for Osteosarcoma: An In Vitro Study
Current Medicinal Chemistry Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design